CMCarolin Miklitz

Carolin Miklitz

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Carolin Miklitz has a total of 71 co-authors. Here are the top co-authors by number of shared publications:

  • Klaus Fliessbach

    Department of Old Age Psychiatry and Cognitive Disorders, University Hospital Bonn and University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127 Bonn, Germany

    3 shared publications
  • Anja Schneider

    Department of Old Age Psychiatry and Cognitive Disorders, University Hospital Bonn and University of Bonn, Bonn, Germany; German Center for Neurodegenerative Diseases (DZNE), Bonn, Venusberg-Campus 1, 53127 Bonn, Germany

    2 shared publications
  • Michael Wagner

    Department of Psychiatry and Psychotherapy, University Hospital Bonn, Bonn, Germany

    2 shared publications
  • Alexander Radbruch

    Department of Diagnostic and Interventional Neuroradiology and Pediatric Neuroradiology University Hospital Bonn Bonn Germany

    1 shared publication
  • Alfredo Ramirez

    German Center for Neurodegenerative Diseases (DZNE), Bonn, Germany

    1 shared publication
  • Alois Martin Sprinkart

    Department of Diagnostic and Interventional Radiology University Hospital Bonn Bonn Germany

    1 shared publication

Latest Publications

  • Open Access

    Locally deployed large language model for real‐world lecanemab eligibility pre‐screening

    by Carolin Miklitz, Maya Shrestha, Wegner Philipp, Nils Henk, Alois Martin Sprinkart, Wolfgang Block, Julian Alexander Luetkens, Alexander Radbruch, Nils Christian Lehnen, Sebastian Nowak

    INTRODUCTION: The introduction of disease‐modifying Alzheimer's therapies requires complex, labor‐intensive patient screening. Cloud‐based large language models (LLMs) could support this task but are often unsuitable for routine care due to data protection constraints. METHODS: We evaluated an on‐premises, open‐weights LLM (gpt‐oss‐120b) for automated extraction of therapy‐relevant variables for lecanemab eligibility from German memory clinic reports. In a two‐stage design, LLM‐based extraction prompts, a deterministic rule‐based extractor, and a shared downstream rule‐based classifier were optimized on a development set ( n = 97) and evaluated on an independent hold‐out set ( n = 99), with expert consensus as ground truth. RESULTS: The LLM‐based pipeline achieved 94% accuracy and a Cohen's kappa of 0.90 on the hold‐out set, significantly surpassing the rule‐based comparator (80% accuracy) and demonstrating performance comparable to human experts. DISCUSSION: A locally deployed, on‐premises LLM may assist eligibility screening as a triage support tool, potentially facilitating access to novel therapies without compromising patient data privacy.

  • Open Access

    Privacy-Preserving Mobile Face Tracking for Assessing Empathic Facial Reactivity: Cross-Sectional Study in Healthy Adults (Preprint)

    by Cem Doğdu, Leon Nissen, Luca Kleineidam, Carolin Miklitz, Johanna Knöferle, Klaus Fliessbach, Lena Marth, Johannes Levin, Elisabeth Kasper, Andreas Hermann, et al.

  • Open Access

    Plasma GFAP outperforms CSF GFAP in detecting amyloid pathology and is associated with increased risk of clinical progression in early Alzheimer’s disease

    by Arda C. Cetindag, Carola G. Schipke, Hermann Esselmann, Niels Kruse, Jens Wiltfang, Anja Schneider, Klaus Fliessbach, Carolin Miklitz, Franziska Maier, Katharina Buerger, et al.


  • Open Access

    Happiness, positive emotions, and subjective well-being in dementia

    by Carolin Miklitz, Klaus Fliessbach, Cornelia McCormick

    Research on non-cognitive features of dementia traditionally focusses on neuropsychiatric symptoms and challenging behavior and thus on negative aspects of the disease. Despite the clinical observation that many patients frequently report subjective well-being and often express positive emotions there is only little research on the definition, measurement and determinants of subjective well-being and happiness in people living with dementia. Furthermore, the few studies there are, examined happiness using retrospective questionnaires and the accounts of relatives or caregivers. However, in dementia, the experiencing self becomes more significant since past and future thinking are fading into the background. Here, we review the relative scarce literature in this field, discuss different psychological constructs and their applicability for dementia research, and suggest methods for measuring the addressed constructs in people with dementia. In particular, we propose methodology to study happiness and positive emotions in the experienced moment of the participants using ecological momentary assessments (EMA). We believe that adequate measures of momentary subjective well-being might become an important outcome parameter in clinical dementia trials beyond the currently used quality of life measures.


  • The impact of COVID-19-related distress on levels of depression, anxiety and quality of life in psychogeriatric patients

    by Carolin Miklitz, Christine Westerteicher, Sina Lippold, Lena Ochs, Anja Schneider, Klaus Fliessbach

    Within the elderly population, psychogeriatric patients may be particularly susceptible to negative mental health effects of the coronavirus crisis. Detailed information about the psychosocial well-being of psychogeriatric patients during the pandemic is still sparse. Here we examined which aspects of subjective experience of the COVID-19 pandemic especially affect levels of depression, anxiety and quality of life in psychogeriatric patients with and without cognitive impairment. A cross-sectional paper survey was conducted during the first German lockdown among patients with a diagnosed psychiatric disorder (≥ 60 years) or a diagnosed neurodegenerative disease (regardless of their age) from the department for neurodegenerative diseases and geriatric psychiatry at the University of Bonn. The WHO-5-, GAD-7- and WHOQOL-old score were used to determine levels of depression, anxiety and quality of life. The second part obtained information about the subjective experience of the COVID-19 pandemic. Statistical analysis included among others principal component analysis and multiple linear regression analysis. COVID-19-related, immediate distress was a strong predictor of elevated symptoms of depression, anxiety and a reduced quality of life. COVID-19-related concerns regarding health and financial security, however, were not significantly associated with negative mental health outcomes. The overall prevalence of symptoms of depression (50.8% [95% CI 43.8–57.6%]) and anxiety (32.7% [95% CI 26.4–39.2%]) among psychogeriatric patients was high. Our findings indicate that psychogeriatric patients are not significantly affected by COVID-19-related concerns but are primarily suffering from emotional consequences resulting from changed living conditions due to the pandemic.